LYRA — Lyra Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $6.45m
- -$15.60m
- $1.53m
Annual income statement for Lyra Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0.285 | 1.36 | 1.56 | 1.53 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22.2 | 43.9 | 57.7 | 68.7 | 97.9 |
| Operating Profit | -22.2 | -43.6 | -56.3 | -67.1 | -96.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -22.1 | -43.5 | -55.3 | -62.6 | -93.4 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -22.1 | -43.5 | -55.3 | -62.7 | -93.4 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -22.1 | -43.5 | -55.3 | -62.7 | -93.4 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -22.2 | -43.5 | -55.3 | -62.7 | -93.4 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -129 | -168 | -90 | -61.9 | -54 |